APLS Apellis Corp Expected net earnings per share growth this year

Official company branding of Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals (APLS), a leader in the treatment of retinal atrophy, is currently countering the expansion of new market entrants through intensified marketing. The annual EPS growth rate reflects current dynamics, with the latest value recorded as -663.70. Management is striving for total niche dominance, while global sales scale the business, transforming costs into net margin growth.

apellis.com (APLS) Earnings per share growth in current year: for the period 07/04/2022 - 05/30/2026

Analytical breakdowns and data insights for company Apellis Pharmaceuticals (APLS)

- stock value and consensus price forecast:
Market Price Apellis Pharmaceuticals, Inc.|APLS - Price Target Chart
- market capitalization data:
Market Capitalization Apellis Corp|APLS - Enterprise Value
- shareholders' equity book value data:
Book Value per Share Apellis Pharmaceuticals|APLS - Company Book Value|Market Capitalization to Net Assets apellis.com|APLS - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital Apellis Pharmaceuticals|APLS - Long-Term Debt to Equity|Short-Term Debt to Equity apellis.com|APLS - Company Debts|Debt to Book Capitalization Ratio Apellis Corp|APLS - Company Long-Term Debts|Short-Term Debt Volume Apellis Pharmaceuticals|Interim Coverage Ratio apellis.com
- earnings and market multiples details:
APLS - Net Income|Expected Net Income Apellis Pharmaceuticals|APLS - Price to Earnings Ratio|Price to Expected Earnings Ratio Apellis Corp|APLS - PEG Multiple|Business Value to Operating Income Before Depreciation Apellis Corp|APLS - Operating profit EBITDA|Net earnings per share (EPS TTM) Apellis Pharmaceuticals|APLS - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months apellis.com|APLS - Earnings per share growth in current year|Expected earnings per share growth for next year Apellis Pharmaceuticals
Basic company analysis:Apellis Pharmaceuticals, Inc., APLS
Signature product of apellis.com

This indicator reflects the annual trend of net income per share, allowing for an assessment of real capital generation efficiency regardless of market volatility. By analyzing the annual EPS growth ratio, an investor determines business sustainability, which for Apellis Pharmaceuticals (APLS) is confirmed by the high margins of its patent-protected exclusive retinal treatment.

Direct competitors

Earnings per share growth rate in current year Alcon Inc (ALC)|Earnings per share growth in current year Bausch + Lomb Corp|Glaukos Medical (GKOS) - Expected net earnings per share growth this year|Earnings growth in current year BLTE|Earnings growth in current year ocutx.com (OCUL)|Earnings per share growth in current year Harrow HROW|VRDN (Viridian Therapeutics Inc) - Earnings per share trend in current year|LENZ Pharma - Earnings growth in current year|Earnings per share growth rate in current year Oaktree Specialty Lending|EyePoint Pharmaceuticals (EYPT) - Earnings per share growth in current year|KOD (kodiak.com) - Earnings per share growth in current year|Earnings per share growth in current year Aldeyra Therapeutics Inc.|Earnings per share growth in current year KALA|Earnings growth in current year IRD|Expected net earnings per share growth this year okyopharma.com|Earnings per share growth in current year Adverum Biotechnologies, Inc. ADVM|Expected net earnings per share growth this year outlooktherapeutics.com (OTLK)|CLSD: Net earnings per share growth this year|Earnings per share increase in current year NBY (NovaBay Pharmaceuticals)|kiorapharma.com (KPRX) - Earnings per share growth in current year|Earnings per share trend in current year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Inc.) - Earnings growth in current year|GHSI: Earnings per share increase in current year|Earnings growth in current year OCUP|Earnings growth in current year Opthea Ltd (OPT)